Elevated level of cell-free plasma DNA is associated with breast cancer

被引：60

作者：

Zhong X.Y. ^{[1
]}

Ladewig A. ^{[1
]}

Schmid S. ^{[1
]}

Wight E. ^{[1
]}

Hahn S. ^{[1
]}

Holzgreve W. ^{[1
]}

机构：

[1] Laboratory for Prenatal Medicine and Gynaecological Oncology, Department of Obstetrics and Gynaecology, University of Basel, 4031 Basel

来源：

Archives of Gynecology and Obstetrics | 2007年 / 276卷 / 4期

关键词：

Breast cancer; Cancer biomarkers; Cancer prognosis; Cell-free DNA;

D O I：

10.1007/s00404-007-0345-1

中图分类号：

学科分类号：

摘要：

Background: We analysed cell-free DNA (cfDNA) in the plasma of patients with both malignant and benign breast lesions by real-time quantitative PCR to determine whether the finding may have diagnostic and prognostic implications. Methods: Plasma samples were obtained from 33 patients with breast cancer, 32 patients with benign breast lesions and 50 healthy women as normal controls. Circulatory cfDNA was extracted from the plasma samples and quantified by real-time quantitative PCR for the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene. Results: The mean concentrations of cfDNA in the plasma samples from patients with breast cancer, patients with benign breast lesions and normal controls were 2,285, 1,368 and 1,489 genome equivalents (GE) per millilitre, respectively. The level of cfDNA in the breast cancer group was significantly higher than those in the benign lesion group and control group (P = 0.007 and 0.013, respectively). These findings were associated with malignant tumour size. The levels of the cfDNA were high in patients with lymph node involvement and distant metastasis. Conclusions: Our results suggest that levels of cfDNA in the plasma are elevated in malignant breast cancer and correlated with tumour size. These findings could have diagnostic and prognostic value for malignant breast tumours. © 2007 Springer-Verlag.

引用

页码：327 / 331

页数：4

共 29 条

[1]

Pantel K., Muller V., Auer M., Nusser N., Harbeck N., Braun S., Detection and clinical implications of early systemic tumour cell dissemination in breast cancer, Clin Cancer Res, 9, pp. 6326-6334, (2003)

[2]

Diel I.J., Solomayer E.F., Bastert G., Bisphosphonates and the prevention of metastasis: First evidences from preclinical and clinical studies, Cancer, 88, pp. 3080-3088, (2000)

[3]

Diel I.J., Antitumour effects of bisphosphonates: First evidence and possible mechanisms, Drugs, 59, pp. 391-399, (2000)

[4]

Diel I.J., Mundy G.R., Bisphosphonates in the adjuvant treatment of cancer: Experimental evidence and first clinical results. International Bone and Cancer Study Group (IBCG), Br J Cancer, 82, pp. 1381-1386, (2000)

[5]

Diel I.J., Solomayer E.F., Bastert G., Micrometastatic cells in the bone marrow of patients with breast carcinoma], Radiologe, 40, pp. 681-687, (2000)

[6]

Pantel K., Woelfle U., Detection and molecular characterisation of disseminated tumour cells: Implications for anti-cancer therapy, Biochim Biophys Acta, 1756, pp. 53-64, (2005)

[7]

Solomayer E.F., Diel I.J., Meyberg G.C., Gollan C., Bastert G., Metastatic breast cancer: Clinical course, prognosis and therapy related to the first site of metastasis, Breast Cancer Res Treat, 59, pp. 271-278, (2000)

[8]

Bauer K.D., De La Torre-Bueno J., Diel I.J., Hawes D., Decker W.J., Priddy C., Bossy B., Ludmann S., Yamamoto K., Masih A.S., Espinoza F.P., Harrington D.S., Reliable and sensitive analysis of occult bone marrow metastases using automated cellular imaging, Clin Cancer Res, 6, pp. 3552-3559, (2000)

[9]

Anker P., Stroun M., Circulating DNA in plasma or serum, Medicina (B Aires), 60, pp. 699-702, (2000)

[10]

Nawroz-Danish H., Eisenberger C.F., Yoo G.H., Wu L., Koch W., Black C., Ensley J.F., Wei W.Z., Sidransky D., Microsatellite analysis of serum DNA in patients with head and neck cancer, Int J Cancer, 111, pp. 96-100, (2004)

← 1 2 3 →